Related Experiment Video
Updated: May 13, 2025
06:02
Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers
Published on: February 20, 2017
7.5K
The Persistent Power of the Taxane/Platin Chemotherapy
Lucy B Xu1, Elizabeth R Smith2,3, Vasili Koutouratsas4
1Department of Biology, University of Miami, Miami, FL 33136, USA.
Cancers
|April 14, 2025
Summary
Despite decades of research, targeted cancer therapies struggle to replace taxane/platinum chemotherapy. This is likely because cancer cells develop resistance to programmed cell death, a key mechanism targeted by these newer drugs.
Area of Science:
- Oncology
- Cancer Biology
- Pharmacology
Background:
- Taxane and platinum chemotherapy combinations, developed over 40 years ago, remain a cornerstone treatment for many cancers.
- Despite advances in understanding cancer genetics and pathways, targeted therapies have not replaced traditional cytotoxic chemotherapy.
Purpose of the Study:
- To investigate why targeted cancer therapies have not surpassed the efficacy of established taxane/platinum regimens.
- To propose a novel explanation for the limited success of targeted therapies, focusing on cancer cell resistance mechanisms.
Main Methods:
- Review of existing literature on cancer chemotherapy and targeted therapy mechanisms.
- Analysis of the proposed mechanisms of action for taxanes, platinum agents, and targeted therapies.
- Hypothesizing the role of programmed cell death pathway desensitization in cancer progression.
Main Results:
- Targeted therapies aim to induce programmed cell death (apoptosis) in cancer cells.
- Cancer cells undergoing neoplastic transformation and malignant progression often desensitize their programmed cell death pathways.
- Taxanes and platinum agents appear to kill cancer cells via physical disruption of nuclear membranes, independent of apoptosis.
Conclusions:
- The desensitization of programmed cell death pathways in cancer cells limits the effectiveness of targeted therapies.
- The non-apoptotic mechanism of action of taxanes and platinum agents contributes to their enduring efficacy.
- Future cancer therapy development should explore non-programmed cell death strategies to enhance treatment outcomes and potentially replace or improve current regimens.
Related Concept Videos
01:15Drugs that Stabilize Microtubules
1.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
1.9K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
140
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
140
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
152
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
152
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
190
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
190